Mumbai-based pharma major Wockhardt, which is gearing up to launch its promising antibiotic candidate Zaynich soon, on Friday announced a shift in its United States (US) operations.
The Indian pharma giant revealed that it has decided to exit the generics pharmaceutical segment in the country.
Uploaded by:
Rediff Video Desk
on Sat, 12 Jul 2025 22:25:35 +0530
Views: 91
Tags: Wockhardt exits US generics biz, to focus on innovation